179 related articles for article (PubMed ID: 9140699)
1. Involvement of CYP3A4 and CYP2D6 in the metabolism of haloperidol.
Fang J; Baker GB; Silverstone PH; Coutts RT
Cell Mol Neurobiol; 1997 Apr; 17(2):227-33. PubMed ID: 9140699
[TBL] [Abstract][Full Text] [Related]
2. In vitro study on the involvement of CYP1A2, CYP2D6 and CYP3A4 in the metabolism of haloperidol and reduced haloperidol.
Pan L; Belpaire FM
Eur J Clin Pharmacol; 1999 Oct; 55(8):599-604. PubMed ID: 10541779
[TBL] [Abstract][Full Text] [Related]
3. In vitro characterization of the metabolism of haloperidol using recombinant cytochrome p450 enzymes and human liver microsomes.
Fang J; McKay G; Song J; Remillrd A; Li X; Midha K
Drug Metab Dispos; 2001 Dec; 29(12):1638-43. PubMed ID: 11717183
[TBL] [Abstract][Full Text] [Related]
4. Involvement of human cytochrome P450 3A4 in reduced haloperidol oxidation.
Kudo S; Odomi M
Eur J Clin Pharmacol; 1998 May; 54(3):253-9. PubMed ID: 9681669
[TBL] [Abstract][Full Text] [Related]
5. Involvement of CYP3A4 in the metabolism of bromperidol in vitro.
Sato S; Someya T; Shioiri O; Koitabashi T; Inoue Y
Pharmacol Toxicol; 2000 Mar; 86(3):145-8. PubMed ID: 10752674
[TBL] [Abstract][Full Text] [Related]
6. In-vitro characterization of the cytochrome P450 isoenzymes involved in the back oxidation and N-dealkylation of reduced haloperidol.
Pan LP; De Vriendt C; Belpaire FM
Pharmacogenetics; 1998 Oct; 8(5):383-9. PubMed ID: 9825830
[TBL] [Abstract][Full Text] [Related]
7. Characterization of the cytochrome P450 isoenzymes involved in the in vitro N-dealkylation of haloperidol.
Pan LP; Wijnant P; De Vriendt C; Rosseel MT; Belpaire FM
Br J Clin Pharmacol; 1997 Dec; 44(6):557-64. PubMed ID: 9431831
[TBL] [Abstract][Full Text] [Related]
8. CYP3A is responsible for N-dealkylation of haloperidol and bromperidol and oxidation of their reduced forms by human liver microsomes.
Tateishi T; Watanabe M; Kumai T; Tanaka M; Moriya H; Yamaguchi S; Satoh T; Kobayashi S
Life Sci; 2000 Nov; 67(24):2913-20. PubMed ID: 11133003
[TBL] [Abstract][Full Text] [Related]
9. Asymmetric redox reactions in human liver stereoselective oxidation of optically active dihydrohaloperidols, dihydrobromoperidols and stereospecific reduction of haloperidol and bromoperidol.
Takeshita M; Miura M; Ohkubo T; Sugawara K
Enantiomer; 2000; 5(2):189-95. PubMed ID: 10857058
[TBL] [Abstract][Full Text] [Related]
10. Effect of quinidine on the interconversion kinetics between haloperidol and reduced haloperidol in humans: implications for the involvement of cytochrome P450IID6.
Young D; Midha KK; Fossler MJ; Hawes EM; Hubbard JW; McKay G; Korchinski ED
Eur J Clin Pharmacol; 1993; 44(5):433-8. PubMed ID: 8359179
[TBL] [Abstract][Full Text] [Related]
11. Oxidation of reduced haloperidol to haloperidol: involvement of human P450IID6 (sparteine/debrisoquine monooxygenase).
Tyndale RF; Kalow W; Inaba T
Br J Clin Pharmacol; 1991 Jun; 31(6):655-60. PubMed ID: 1867960
[TBL] [Abstract][Full Text] [Related]
12. Nortriptyline E-10-hydroxylation in vitro is mediated by human CYP2D6 (high affinity) and CYP3A4 (low affinity): implications for interactions with enzyme-inducing drugs.
Venkatakrishnan K; von Moltke LL; Greenblatt DJ
J Clin Pharmacol; 1999 Jun; 39(6):567-77. PubMed ID: 10354960
[TBL] [Abstract][Full Text] [Related]
13. Metabolism of the active metabolite of quetiapine, N-desalkylquetiapine in vitro.
Bakken GV; Molden E; Knutsen K; Lunder N; Hermann M
Drug Metab Dispos; 2012 Sep; 40(9):1778-84. PubMed ID: 22688609
[TBL] [Abstract][Full Text] [Related]
14. Identification of human liver cytochrome P450 enzymes that metabolize the nonsedating antihistamine loratadine. Formation of descarboethoxyloratadine by CYP3A4 and CYP2D6.
Yumibe N; Huie K; Chen KJ; Snow M; Clement RP; Cayen MN
Biochem Pharmacol; 1996 Jan; 51(2):165-72. PubMed ID: 8615885
[TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetics of haloperidol: an update.
Kudo S; Ishizaki T
Clin Pharmacokinet; 1999 Dec; 37(6):435-56. PubMed ID: 10628896
[TBL] [Abstract][Full Text] [Related]
16. Involvement of CYP3A4, CYP2C8, and CYP2D6 in the metabolism of (R)- and (S)-methadone in vitro.
Wang JS; DeVane CL
Drug Metab Dispos; 2003 Jun; 31(6):742-7. PubMed ID: 12756206
[TBL] [Abstract][Full Text] [Related]
17. Stereoselective differences in the cytochrome P450-dependent dealkylation and demethylenation of N-methyl-benzodioxolyl-butanamine (MBDB, Eden) enantiomers.
Meyer MR; Peters FT; Maurer HH
Biochem Pharmacol; 2009 Jun; 77(11):1725-34. PubMed ID: 19428327
[TBL] [Abstract][Full Text] [Related]
18. Identification of three cytochrome P450 isozymes involved in N-demethylation of citalopram enantiomers in human liver microsomes.
Rochat B; Amey M; Gillet M; Meyer UA; Baumann P
Pharmacogenetics; 1997 Feb; 7(1):1-10. PubMed ID: 9110356
[TBL] [Abstract][Full Text] [Related]
19. Involvement of CYP2D6, CYP3A4, and other cytochrome P-450 isozymes in N-dealkylation reactions.
Coutts RT; Su P; Baker GB
J Pharmacol Toxicol Methods; 1994 Aug; 31(4):177-86. PubMed ID: 7949373
[TBL] [Abstract][Full Text] [Related]
20. Biotransformation of parathion in human liver: participation of CYP3A4 and its inactivation during microsomal parathion oxidation.
Butler AM; Murray M
J Pharmacol Exp Ther; 1997 Feb; 280(2):966-73. PubMed ID: 9023313
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
